Related Experiment Videos
Eicosanoids, other fatty acid metabolites and the cardiovascular system: are the present antithrombotic approaches
M R Buchanan1, S J Brister, M C Bertomeu
1McMaster University, Dept Pathology, McMaster Clinic, Hamilton General Hospital, Canada.
Insights
Current antithrombotic therapies are suboptimal. This review explores novel strategies targeting vascular endothelium-derived antithrombotic agents, like 13-hydroxyoctadecadienoic acid (13-HODE), to improve thrombosis treatment.
Area of Science:
- Vascular Biology
- Thrombosis Research
- Pharmacology
Background:
- Standard antithrombotic therapies using antiplatelet and anticoagulant drugs are effective but not optimal for preventing and treating thrombosis.
- The vascular endothelium produces endogenous antithrombotic agents, including prostacyclin (PGI2), tissue plasminogen activator, thrombomodulin, and 13-hydroxyoctadecadienoic acid (13-HODE).
- These endothelial factors play a crucial role in regulating vascular thrombogenicity and inhibiting thrombogenesis.
Purpose of the Study:
- To review current and emerging strategies for antithrombotic therapy.
- To discuss the rationale behind leveraging endothelial antithrombotic agents.
- To introduce a novel antithrombotic approach based on experimental data, aiming to overcome limitations of existing treatments.
Main Methods:
- Literature review of existing antithrombotic therapies and endothelial antithrombotic mechanisms.
- Analysis of recent experimental data on novel antithrombotic strategies.
- Discussion of the potential benefits and limitations of different therapeutic approaches.
Main Results:
- Current antiplatelet and anticoagulant therapies have limitations and side effects.
- Endothelial-derived factors offer promising targets for new antithrombotic strategies.
- A novel approach utilizing these endogenous agents may provide a safer and more effective alternative.
Conclusions:
- Novel antithrombotic strategies focusing on endothelial-derived factors represent a promising advancement.
- Targeting agents like 13-HODE could offer a more refined approach to managing thrombosis.
- Further research and development of these alternative therapies are warranted to improve patient outcomes.
Abstract:
Antiplatelet +/- anticoagulant drugs are currently used as the standard treatment to prevent and treat thrombosis. While this approach is beneficial, it is not optimal. Recent evidence suggests that constituents of the vascular endothelium play an important role in regulating vessel wall thrombogenecity, thereby inhibiting thrombogenesis. These include constituents such as PGI2, tissue plasminogen activator, thrombomodulin and the lipoxygenase fatty acid metabolite derived from linoleic acid, 13-hydroxyoctadecadienoic acid (13-HODE). Consequently, new strategies have been developed to maximize the use of these agents for antithrombotic therapy. We will review these different approaches, discuss their rationale, and based upon recent experimental data, introduce an alternative approach for antithrombotic therapy which may circumvent a number of limitations and side-effect of the currently used drugs.